Mira Pharmaceuticals Inc
NASDAQ:MIRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mira Pharmaceuticals Inc
Operating Income
Mira Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Mira Pharmaceuticals Inc
NASDAQ:MIRA
|
Operating Income
-$10.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-174%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$26.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$16.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
23%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$19.9B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$26.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$29.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
Mira Pharmaceuticals Inc
Glance View
Mira Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Baltimore, Maryland and currently employs 1 full-time employees. The company went IPO on 2023-08-03. MIRA Pharmaceuticals, Inc. is a clinical development stage biopharmaceutical company. The firm is focused on the development and commercialization of molecular synthetic cannabinoid analog for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. The firm is developing its product candidate, MIRA1a, for the treatment of neuropsychiatric, inflammatory and neurologic diseases and disorders. MIRA1a is a synthetic cannabinoid analog for treating anxiety and chronic pain by striking a balance between the beneficial effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors.
See Also
What is Mira Pharmaceuticals Inc's Operating Income?
Operating Income
-10.5m
USD
Based on the financial report for Dec 31, 2025, Mira Pharmaceuticals Inc's Operating Income amounts to -10.5m USD.
What is Mira Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-174%
Over the last year, the Operating Income growth was -31%. The average annual Operating Income growth rates for Mira Pharmaceuticals Inc have been -14% over the past three years , -174% over the past five years .
